Physician profile
Mark Spencer
NPI 1508818097
$1,007.35
in general payments reported to CMS, 2019-2025
12 companies · $268 in 2025
The $268 reported for 2025 was more than what 85% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $19.86 · 2021: $171 · 2022: $72.33 · 2023: $223 · 2024: $107 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561 · Education: $37.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.57 |
| Education | $37.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $498.21 | 2019-2025 | Bridion |
| Axogen | $155.79 | 2025 | |
| Boston Scientific Corporation | $103.96 | 2021 | |
| Access Pro Medical, LLC | $67.63 | 2023 | Matriderm |
| Nevro Corp. | $46.50 | 2019 | |
| Janssen Biotech, INC. | $33.60 | 2025 | Tremfya |
| Abbvie INC. | $24.61 | 2025 | |
| Conmed Corporation | $23.01 | 2025 | Airseal |
| Allergan, INC. | $16.07 | 2019 | |
| Ambu INC. | $13.30 | 2022 | |
| Heron Therapeutics, INC. | $12.79 | 2023 | Zynrelef |
| Astrazeneca Pharmaceuticals Lp | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.